Induction of Intestinal Tumors and Lymphomas in C57BL/6N Mice by a Food-borne Carcinogen, 2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine

Masako Ochiai,1 Hiroshi Imai,1, 2 Takashi Sugimura,1 Minako Nagao1 and Hitoshi Nakagama1, 3
1Biochemistry Division, National Cancer Center Research Institute, 5-1-1 Tsukiji, Chuo-ku, Tokyo 104-0045

2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) is the most abundant mutagenic and carcinogenic heterocyclic amine contained in cooked meat and fish. Although PhIP has been demonstrated to induce various types of tumors in rats, lymphomas predominated in mice using the CDF1 strain. To investigate the carcinogenic activity of PhIP on other organs in mice with a different genetic background, PhIP was administered to C57BL/6N mice. After a 40-week administration of 300 ppm of PhIP in a high-fat diet followed by continuous feeding with a high fat diet, C57BL/6N mice developed adenomas and adenocarcinomas in the small intestine, the incidences being 52% in males and 68% in females at weeks 95 and 70, respectively. Lymphomas of B-cell origin also developed in both sexes as frequently as in the CDF1 strain, incidences being 48% in males and 32% in females. Although the incidence in PhIP-treated female mice did not differ from that in the control mice, lymphomas developed significantly earlier in the PhIP-treated mice. The present study demonstrated that the intestinal tract is another potential target of PhIP-induced carcinogenesis in mice, and that the carcinogenic activity of PhIP could be affected by the genetic background of the animals.

Key words: PhIP — Strain difference — Intestinal tumor — Lymphoma — Mice

2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) is the most abundant mutagenic and carcinogenic heterocyclic amine and is widely used for carcinogenesis studies in rodents. PhIP has been shown to induce colon cancers,2, 3) prostate cancers4) and lymphomas5) in F344 male rats. Cecum and colon cancers are induced in Nagase analbuminemic male rats,6) and mammary cancers in F3443) and Sprague-Dawley female rats.7) Despite this wide range of organs as carcinogenic targets of PhIP in rats, only lymphomas have been reported to be induced in mice after a long-term exposure using the CDF1 strain.8) Recently, 2-amo-no-3,4-dimethylimidazo[4,5-f]quino line (MeIQ), which is another type of heterocyclic amine and is widely used for carcinogenesis studies in rodents, was demonstrated to induce colon, cecum and liver cancers in C57BL/6N mice, and the target organs of MeIQ in C57BL/6N were different from those in CDF1.9) This indicates that target organs of heterocyclic amines could vary among different mouse strains, and substantial contributions by the genetic backgrounds of mice need to be taken into consideration. In the present study, the carcinogenic activity of PhIP in mice was investigated using the C57BL/6N strain. C57BL/6N mice have been widely utilized for a variety of animal experiments, including gene-disruption studies, and are highly susceptible to the induction of colon cancers by a synthetic alkylating agent, 1,2-dimethylhydrazine (DMH).10, 11) A 40-week feeding of 300 ppm PhIP in a high-fat (HF) diet, followed by a continuous feeding of the HF diet alone, was conducted and the carcinogenic activity of PhIP in various organs was analyzed.

MATERIALS AND METHODS

Experimental protocol C57BL/6N mice of both sexes were purchased from CLEA Japan (Tokyo) at the age of 6 weeks. PhIP was purchased from the Nard Institute (Osaka) and added to the diet. After a one-week acclimatization to the housing conditions and an AIN-93G diet, 26 or 27 mice of both sexes were fed a HF diet, a modified AIN-93G diet (Dyets, Bethlehem, PA) supplemented with 23% hydrogenated vegetable oil (PRIMEX; Dyets), containing 300 ppm of PhIP. After a 40-week administration of PhIP, mice were continuously fed the HF diet until the termination of experiment. Male and female mice fed only the HF diet without PhIP were used as controls.

Histological examination The mice were sacrificed and autopsied when they became moribund or at the termination of experiments. All organs were carefully examined macroscopically for the presence of tumors and then fixed in neutralized 10% formalin at 4°C, and embedded in paraffin blocks. Paraffin sections were cut into 3.5 μm thick-
ness, then stained with hematoxylin-eosin (H&E), and histopathological analyses were performed under light microscopic observation.

**Immunostaining of lymphocyte cell-surface antigens**

Immunohistochemical staining of T- and B-cell surface antigens was carried out as described above. Monoclonal antibodies of anti-CD3 (CD3-12, Novocastra Lab., Newcastle upon Tyne, UK) and biotinylated anti-CD45R/B220 (RA3-6B2, PharMingen, San Diego, CA) were used to detect T- and B-cell surface antigens, respectively. Sections were pretreated in an autoclave for 10 min at 120°C in 1 mM EDTA (pH 8.0) for CD3, and 10 mM citrate buffer (pH 6.0) for CD45R/B220, and the ABC reagent (VECTASTAIN Elite ABC kit, Vector Lab., Burlingame, CA) was used to visualize the respective cell surface antigens.

**Statistical analysis**

Survival rates were calculated by the Kaplan-Meier method. The differences in survival rates and cumulative incidences of tumors were analyzed by a log-rank test, and tumor incidences by $\chi^2$ test. All statistical analysis was performed using the SPSS software for Macintosh (SPSS Japan, Inc., Tokyo), and the differences were considered to be significant when the $P$ values were less than 0.05.

**RESULTS**

**Effects of PhIP on survival**

Administration of PhIP caused the body weights of surviving male and female mice to gradually decrease to approximately 80% of the control by experimental week 40, and they stayed within the range of 80–90% of the control until the termination of experiments (data not shown). The first male mouse died of cancer at week 28, of adenocarcinoma in the small intestine, and the first female died of lymphoma at week 33. All the male and female mice that died after these respective dates were counted as effective for the carcinogenesis study. Some of the mice developed tumors in two or more organs. The experiments were terminated at 95 and 70 weeks for male and female mice, respectively (Fig. 1). Survival rates of PhIP-treated mice were lower than those of untreated mice of both males and females ($P<0.05$).

**Carcinogenicity in the gastrointestinal tract**

In the gastrointestinal tract, small intestinal tumors were observed in 52% of male and 68% of female mice by the termination of experiments, and tumor incidences in both sexes were significantly higher than those of untreated mice (Table I). The majority of tumors in PhIP-treated groups were adenocarcinomas (Fig. 2A), accounting for 81% (17 of 21) in males and 86% (24 of 28) in females, with the remainder

![Survival curve of C57BL/6N male (A) and female (B) mice. Solid lines (—) represent the survival of mice in PhIP-ununtreated control groups. Dashed lines (----) indicate the survival in PhIP-treated groups.](image)
being adenomas (Fig. 2B). Four tumors that developed in the control groups, 3 in males and 1 in a female, were also diagnosed as adenocarcinomas. No difference in histopathological appearance or grade of tumors was observed between PhIP-treated and control groups. Tumor sites were distributed along the entire small intestine, but mostly in the middle and proximal parts (data not shown). Three male mice in the PhIP-treated group developed adenocarcinomas in the cecum. No tumors were detected in the esophagus, stomach or colon.

**Carcinogenicity in lymphoid tissues** Administration of PhIP also increased the incidence of lymphoma in male mice (Table I, \( P < 0.01 \)). In female mice, although no increase was observed in its incidence, lymphomas developed much earlier in PhIP-treated mice than in the control mice, as is depicted in Fig. 3 (\( P < 0.05 \)). Lymphomas developed mainly in the mesenchymal lymph nodes (Fig. 4A), and occasionally in the liver, spleen and lungs (Fig. 4B). Five of 12 lymphomas that developed in PhIP-treated male mice were subjected to immunohistochemical analysis. All of them were mainly composed of CD45R/B220 positive cells with a few CD3-positive cells (Fig. 5), and were diagnosed as lymphomas of B-cell origin. Lymphomas that developed in PhIP-treated female mice and those in control mice were also of B-cell origin (data not shown), and no differences were observed histologically between PhIP-treated and control groups.

**Carcinogenicity in other organs** Liver tumors, being mostly hepatocellular carcinomas and occasionally adenomas or hepatoblastomas, developed at a high frequency especially in male mice, the incidences being 80% in the control mice and 40% in the PhIP-treated mice. In the lung, 4 tumors (1 adenocarcinoma in a male and 3 adenomas in females) developed spontaneously in the control groups, but no tumor was induced in the PhIP-treated groups. None of the mice of either sex developed tumors in mammary glands or prostate gland by macroscopic observation.
DISCUSSION

As described earlier, when PhIP was administered in the diet, predominant induction of lymphomas has so far been reported in mice, although PhIP has been found to induce mutations predominantly in the intestines using “Muta,”

\[ \text{lacI} \]

\[ \text{Dlb-I} \]

\[ \text{gpt} \]

transgenic mice. The present study demonstrated that C57BL/6N mice were susceptible to the induction of intestinal tumors, mainly in the small intestine, and of lymphomas after a 40-week continuous feeding of PhIP on a HF diet. Our results indicate an apparently different spectrum of target organs from that of PhIP in CDF1 mice. These differences are considered to be caused by different genetic effects between C57BL/6N and CDF1 mice. Modifying effects by genetic background on the development of intestinal tumors have also been reported in DMH-induced colon carcinogenesis in mice. Klein et al. recently reported that DNA repair-deficient XPA\(^{-/-}\) mice, generated on the C57BL/6 genetic background, were extremely susceptible to intestinal toxicity of PhIP and to the development of tumors in the small intestine. They also observed the development of one small intestinal adenoma in one of seven wild-type C57BL/6 female mice after a 3-month exposure to 25 ppm of PhIP in diet with an additional observation period of 9 months.

It is interesting to note that the majority of intestinal tumors arose in the small intestine, not in the colon, which

Fig. 4. Microscopic findings of lymphomas in a mesenchymal lymph node (A) and invasion of lymphoma in the liver (B) of a C57BL/6N male mouse treated with PhIP. H&E staining, ×50.

Fig. 5. Immunohistochemical staining of a lymphoma induced in a C57BL/6N male mouse, ×80. A, anti-CD45R/B220 antibody (B-cell marker); B, anti-CD3 antibody (T-cell marker).
is one of the main target organs of PhIP in rats.\textsuperscript{2,3} Since the level of PhIP-DNA adducts in the small intestine were demonstrated to be almost equivalent to that in the colon,\textsuperscript{17} some other unknown modifying factors may exist to generate the differential susceptibility between the small intestine and colon in mice.

C57BL/6N mice were also susceptible to the induction of lymphomas of B-cell origin. In female mice, although the incidence of lymphomas did not differ statistically from that of the control mice, the average experimental duration when lymphomas were detected was significantly different from the control group, the average experimental duration of lymphomas did not differ statistically from the control mice. It is indeed important to take into consideration the effect of death due to other tumors on survival time, when analyzing carcinogenic activities and target organ spectra of carcinogenic compounds. A decrease in liver tumor incidence in male mice is one of the main target organs of PhIP in rats.\textsuperscript{2,3} Since the level of PhIP-DNA adducts in the small intestine were demonstrated to be almost equivalent to that in the colon,\textsuperscript{17} some other unknown modifying factors may exist to generate the differential susceptibility between the small intestine and colon in mice.

The data presented in this report demonstrate the susceptibility of C57BL/6N mice to small intestinal tumors and B-cell lymphomas, and genetic background is considered to be one of the key determinants for the susceptibility of mice to an environmental carcinogen, PhIP. A body of carcinogenesis studies of various compounds has been assessed, though only using a relatively limited number of mice strains. The results of the present study suggest to us that carcinogenesis studies should be conducted using various species and strains of animals in order to investigate the potential carcinogenic activity of PhIP and in its relevance to human carcinogenesis.

**ACKNOWLEDGMENTS**

We thank Dr. Toshihiko Kawamori (Cancer Prevention Division, National Cancer Center Research Institute) for advice on histological identification of tumors. This study was supported by a grant for the Promotion of Fundamental Studies in Health Science from the Organization for Pharmaceutical Safety and Research (OPSR) and a Grant-in-Aid for Research on Human Genome and Gene Therapy (Health Sciences Research Grants).

(Received December 20, 2001/Revised March 4, 2002/Accepted March 8, 2002)

**REFERENCES**

1) Wakabayashi, K., Nagao, M., Esumi, H. and Sugimura, T. Food-derived mutagens and carcinogens. *Cancer Res.*, **52** (Suppl.), 2092s–2098s (1992).

2) Hasegawa, R., Sano, M., Tamano, S., Imaida, K., Shirai, T., Nagao, M., Sugimura, T. and Ito, N. Dose-dependence of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) carcinogenicity in rats. *Carcinogenesis*, **14**, 2553–2557 (1993).

3) Ito, N., Hasegawa, R., Sano, M., Tamano, S., Esumi, H., Takayama, S. and Sugimura, T. A new colon and mammary carcinogen in cooked food, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP). *Carcinogenesis*, **12**, 1503–1506 (1991).

4) Shirai, T., Sano, M., Tamano, S., Takahashi, S., Hirose, M., Futakuchi, M., Hasegawa, R., Imaida, K., Matsumoto, K., Wakabayashi, K., Sugimura, T. and Ito, N. The prostate: a target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) derived from cooked foods. *Cancer Res.*, **57**, 195–198 (1997).

5) Rao, C. V., Rivenson, A., Zang, E., Steele, V., Kelloff, G. and Reddy, B. S. Inhibition of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine-induced lymphoma formation by Oltipraz. *Cancer Res.*, **56**, 3395–3398 (1996).

6) Ochiai, M., Ogawa, K., Wakabayashi, K., Sugimura, T., Nagase, S., Esumi, H. and Nagao, M. Induction of intestinal adenocarcinomas by 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine in Nagase analbuminemic rats. *Jpn. J. Cancer Res.*, **82**, 363–366 (1991).

7) Ghoshal, A., Preisegger, K.-H., Takayama, S., Thorgerisson, S. S. and Snyderwine, E. G. Induction of mammary tumors in female Sprague-Dawley rats by the food-derived carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and effect of dietary fat. *Carcinogenesis*, **15**, 2429–2433 (1994).

8) Esumi, H., Ohgaki, H., Kohzen, E., Takayama, S. and Sugimura, T. Induction of lymphoma in CDF1 mice by the food mutagen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine. *Jpn. J. Cancer Res.*, **80**, 1176–1178 (1989).

9) Fujita, H., Nagano, K., Ochiai, M., Ushijima, T., Sugimura, T., Nagao, M. and Matsushima, T. Difference in target organs in carcinogenesis with a heterocyclic amine, 2-amino-3,4-dimethylimidazo[4,5-f]quinoline, in different strains of mice. *Jpn. J. Cancer Res.*, **90**, 1203–1206 (1999).

10) Diwan, B. A. and Blackman, K. E. Differential susceptibility of 3 sublines of C57BL/6 mice to the induction of colorectal tumors by 1,2-dimethylhydrazine. *Cancer Lett.*, **9**, 111–115 (1980).

11) Fleiszer, D., Hilgers, J. and Skamene, E. Multigenic control of colon carcinogenesis in mice treated with 1,2-dimethylhydrazine. *Curr. Top. Microbiol. Immunol.*, **137**, 243–249 (1988).

12) Lynch, A. M., Gooderham, N. J. and Boobis, A. R. Organ distinctive mutagenicity in Muta\textsuperscript{TM} Mouse after short-term exposure to PhIP. *Mutagenesis*, **11**, 505–509 (1996).

13) Zhang, X. B., Felton, J. S., Tucker, J. D., Urlando, C. and Heddle, J. A. Intestinal mutagenicity of two carcinogenic food mutagens in transgenic mice: 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and amino(\textit{\textalpha})-carboline. *Carcinogenesis*, **17**, 2259–2265 (1996).

14) Brooks, R. A., Gooderham, N. J., Zhao, K., Edwards, R. J., Howard, L. A., Boobis, A. R. and Winton, D. J. 2-Amino-
1-methyl-6-phenylimidazo[4,5-b]pyridine is a potent mutagen in the mouse small intestine. *Cancer Res.*, **54**, 1665–1671 (1994).

15) Masumura, K., Matsui, K., Yamada, M., Horiguchi, M., Ishida, K., Watanabe, M., Ueda, O., Suzuki, H., Kanke, Y., Tindall, K. R., Wakabayashi, K., Sofuni, T. and Nohmi, T. Mutagenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in the new gpt<sup>Δ</sup> transgenic mouse. *Cancer Lett.*, **143**, 241–244 (1999).

16) Klein, J. C., Beems, R. B., Zwart, P. E., Hamzink, M., Zomer, G., van Steeg, H. and van Kreijl, C. F. Intestinal toxicity and carcinogenic potential of the food mutagen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in DNA repair deficient XPA<sup>−/−</sup> mice. *Carcinogenesis*, **22**, 619–626 (2001).

17) Josyula, S. and Schut, H. A. Dietary omega-3 fatty acids as potential inhibitors of carcinogenesis: effect on DNA adduct formation of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) in mice and rats. *Food Chem. Toxicol.*, **37**, 287–296 (1999).